A Sheri1, I E Smith2, S R Johnston2, R A'Hern3, A Nerurkar4, R L Jones5, M Hills6, S Detre6, S E Pinder7, W F Symmans8, M Dowsett9. 1. Breast Unit, Royal Marsden Hospital, London; Academic Department of Biochemistry, Royal Marsden Hospital, London; Breakthrough Breast Cancer Research Centre, London. Electronic address: amna.sheri@icr.ac.uk. 2. Breast Unit, Royal Marsden Hospital, London. 3. Clinical Trials and Statistics Unit, Institute of Cancer Research, London. 4. Department of Pathology, Royal Marsden Hospital, London, UK. 5. Division of Medical Oncology, Seattle Cancer Care Alliance, Seattle, USA. 6. Academic Department of Biochemistry, Royal Marsden Hospital, London. 7. Department of Research Oncology, Kings College, London, UK. 8. Department of Pathology, M.D. Anderson Cancer Centre, USA. 9. Breast Unit, Royal Marsden Hospital, London; Academic Department of Biochemistry, Royal Marsden Hospital, London; Breakthrough Breast Cancer Research Centre, London.
Abstract
BACKGROUND: The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power. PATIENTS AND METHODS: A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer were included in the study. Analyses employed a Cox proportional hazard model. Prognostic indices (PIs) were created adding in Ki67, grade and ER to RCB. Leave-one-out cross-validation was used to reduce bias. The overall change in χ(2) of the best model for each index was used to compare the prognostic ability of the different indices. RESULTS: All PIs provided significant prognostic information for patients with residual disease following neoadjuvant chemotherapy. RPCB (χ(2) = 61.4) was significantly more prognostic than either RCB (χ(2) = 38.1) or Ki67 (χ(2) = 53.8) alone P < 0.001. A PI incorporating RCB, Ki67 grade and ER provided the most prognostic information overall and gave χ(2) = 73.8. CONCLUSIONS: This study provides proof of principle that the addition of post-treatment Ki67 to RCB improves the prediction of long-term outcome. Prediction may be further improved by addition of post-treatment grade and ER and warrants further investigation for estimating post-neoadjuvant risk of recurrence. These indices may have utility in stratifying patients for novel therapeutic interventions after neoadjuvant chemotherapy.
BACKGROUND: The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power. PATIENTS AND METHODS: A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer were included in the study. Analyses employed a Cox proportional hazard model. Prognostic indices (PIs) were created adding in Ki67, grade and ER to RCB. Leave-one-out cross-validation was used to reduce bias. The overall change in χ(2) of the best model for each index was used to compare the prognostic ability of the different indices. RESULTS: All PIs provided significant prognostic information for patients with residual disease following neoadjuvant chemotherapy. RPCB (χ(2) = 61.4) was significantly more prognostic than either RCB (χ(2) = 38.1) or Ki67 (χ(2) = 53.8) alone P < 0.001. A PI incorporating RCB, Ki67 grade and ER provided the most prognostic information overall and gave χ(2) = 73.8. CONCLUSIONS: This study provides proof of principle that the addition of post-treatment Ki67 to RCB improves the prediction of long-term outcome. Prediction may be further improved by addition of post-treatment grade and ER and warrants further investigation for estimating post-neoadjuvant risk of recurrence. These indices may have utility in stratifying patients for novel therapeutic interventions after neoadjuvant chemotherapy.
Authors: Elizabeth A Mittendorf; Jose Vila; Susan L Tucker; Mariana Chavez-MacGregor; Benjamin D Smith; W Fraser Symmans; Aysegul A Sahin; Gabriel N Hortobagyi; Kelly K Hunt Journal: JAMA Oncol Date: 2016-07-01 Impact factor: 31.777
Authors: W Fraser Symmans; Caimiao Wei; Rebekah Gould; Xian Yu; Ya Zhang; Mei Liu; Andrew Walls; Alex Bousamra; Maheshwari Ramineni; Bruno Sinn; Kelly Hunt; Thomas A Buchholz; Vicente Valero; Aman U Buzdar; Wei Yang; Abenaa M Brewster; Stacy Moulder; Lajos Pusztai; Christos Hatzis; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2017-01-30 Impact factor: 44.544
Authors: Paula Cabrera-Galeana; Wendy Muñoz-Montaño; Fernando Lara-Medina; Alberto Alvarado-Miranda; Victor Pérez-Sánchez; Cynthia Villarreal-Garza; R Marisol Quintero; Fany Porras-Reyes; Enrique Bargallo-Rocha; Ignacio Del Carmen; Alejandro Mohar; Oscar Arrieta Journal: Oncologist Date: 2018-02-28
Authors: Ryan L Powles; Vikram B Wali; Xiaotong Li; William E Barlow; Zeina Nahleh; Alastair M Thompson; Andrew K Godwin; Christos Hatzis; Lajos Pusztai Journal: Clin Cancer Res Date: 2020-01-09 Impact factor: 12.531
Authors: Jeremy St John Thomas; Elena Provenzano; Louise Hiller; Janet Dunn; Clare Blenkinsop; Louise Grybowicz; Anne-Laure Vallier; Ioannis Gounaris; Jean Abraham; Luke Hughes-Davies; Karen McAdam; Stephen Chan; Rizvana Ahmad; Tamas Hickish; Stephen Houston; Daniel Rea; Carlos Caldas; John Ms Bartlett; David Allan Cameron; Richard Laurence Hayward; Helena Margaret Earl Journal: Mod Pathol Date: 2017-05-26 Impact factor: 7.842
Authors: O Burgués; Mª Á López-García; B Pérez-Míes; P Santiago; B Vieites; J F García; V Peg Journal: Clin Transl Oncol Date: 2017-08-09 Impact factor: 3.405
Authors: Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans Journal: Mod Pathol Date: 2015-07-24 Impact factor: 7.842
Authors: V Bossuyt; E Provenzano; W F Symmans; J C Boughey; C Coles; G Curigliano; J M Dixon; L J Esserman; G Fastner; T Kuehn; F Peintinger; G von Minckwitz; J White; W Yang; S Badve; C Denkert; G MacGrogan; F Penault-Llorca; G Viale; D Cameron Journal: Ann Oncol Date: 2015-05-27 Impact factor: 32.976